Replies to post #248308 on Biotech Values

[dewophile]

The selling point for these healthier patients is to get better 1-2 days faster and to lower risk of long Covid. But sales to low risk patients is always going to be more modest unless you have more virulent variants I think
Ironically the drug interactions matter more for the higher risk patients (who not surprisingly take more drugs w potential interactions)

[Jake2234]

Too bad that it’s not available to them. And it never will be